Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
designed a Pt ()-based responsive nanoreactor modified by Cu 2+ -based MOF (termed CuMOF@Pt ()) for enhanced chemotherapy via depleting GSH (Xiang et al., 2021)
& Shri, R
BMI distribution has shifted modestly toward lower weight categories over the same period, with the change concentrated in the second half of the period
Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss
Collectively, these effects may contribute to weight loss post-surgery in obese patients, suggesting the functional use of tripeptides for weight loss [182]
Hertz, L., Rothman, D
![glutathione rbc Literature Review] Genetic architecture of the red blood cell proteome in genetically diverse mice reveals central Glutathione production and turnover in –](https://moonlight-paper-snapshot.s3.ap-northeast-2.amazonaws.com/arxiv/genetic-architecture-of-the-red-blood-cell-proteome-in-genetically-diverse-mice-reveals-central-role-of-hemoglobin-beta-cysteine-redox-status-in-maintaining-circulating-glutathione-pools-1.png)
